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Abstract Amyotrophic lateral sclerosis (ALS) and fron-
totemporal lobar degeneration (FTLD) are relentlessly
progressive neurodegenerative disorders with overlapping
clinical, genetic and pathological features. Cytoplasmic
inclusions of fused in sarcoma (FUS) are the hallmark of
several forms of FTLD and ALS patients with mutations in
the FUS gene. FUS is a multifunctional, predominantly
nuclear, DNA and RNA binding protein. Here, we report
that transgenic mice overexpressing wild-type human FUS
develop an aggressive phenotype with an early onset tre-
mor followed by progressive hind limb paralysis and death
by 12 weeks in homozygous animals. Large motor neurons
were lost from the spinal cord accompanied by
neurophysiological evidence of denervation and focal
muscle atrophy. Surviving motor neurons in the spinal cord
had greatly increased cytoplasmic expression of FUS, with
globular and skein-like FUS-positive and ubiquitin-nega-
tive inclusions associated with astroglial and microglial
reactivity. Cytoplasmic FUS inclusions were also detected
in the brain of transgenic mice without apparent neuronal
loss and little astroglial or microglial activation. Hemizy-
gous FUS overexpressing mice showed no evidence of a
motor phenotype or pathology. These findings recapitulate
several pathological features seen in human ALS and
FTLD patients, and suggest that overexpression of wild-
type FUS in vulnerable neurons may be one of the root
causes of disease. Furthermore, these mice will provide a
new model to study disease mechanism, and test therapies.
Introduction
Amyotrophic lateral sclerosis (ALS) and frontotemporal
lobar degeneration (FTLD) are relentlessly progressive
neurodegenerative disorders. ALS is characterised by the
degeneration of motor neurons in the motor cortex and
spinal cord, progressive paralysis and ultimately death due
to respiratory failure [9, 46]. FTLD is the second most
common cause of dementia with an onset before 65 years.
It is characterised by focal atrophy of the frontal and/or
temporal lobes, causing changes in personality, behaviour
and language [52]. ALS and FTLD are increasingly
recognised as the phenotypic ends of a clinical spectrum as
*15 % of patients with ALS have cognitive and language
deficits akin to FTLD [47]. Conversely, around 15 % of
people with FTLD develop clinical signs of ALS [32, 40].
ALS and FTLD also have overlapping molecular
pathology [31] as *95 % of ALS cases and *50 % of
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FTLD have neuronal cytoplasmic inclusions (NCIs) con-
taining the TAR DNA binding protein (TDP-43) [35, 45].
TDP-43 binds to a large number of RNA targets and is
involved in the regulation of transcription, splicing and
trafficking [51]. In a minority of ALS and/or FTLD cases,
cytoplasmic aggregation of TDP-43 and its loss from the
nucleus is associated with pathogenic mutations in the
genes encoding TDP-43 (TARDBP[50]), progranulin
(PGRN [33]), valosin containing protein (VCP[42]) and
Ubiquilin 2 (UBQLN2 [10]).
Mutations in another RNA binding protein, fused in
sarcoma (FUS), have been identified in*4 % of autosomal
dominant familial ALS [28, 55] and in rare cases of FTLD
[54]. FUS is ubiquitously expressed and plays an important
role in the regulation of RNA transcription, splicing and
transport [4, 15, 58]. Although predominantly nuclear in
distribution under physiological conditions, in patients with
pathogenic mutations FUS protein accumulates in inclu-
sions in the cytoplasm of lower motor neurons in the spinal
cord [11, 28, 34, 55]. Unlike many other neurodegenerative
diseases, mutant FUS aggregates in ALS are not decorated
by ubiquitin or p62 [55]. The majority of FUS mutations
occur in the extreme C-terminus of the protein, which
contains a nuclear localisation signal [13], thus it has been
proposed that either loss of protein from the nucleus, or
toxicity of protein aggregates accumulated in the cytoplasm
leads to neurodegeneration [12, 39].
Cytoplasmic and nuclear FUS inclusions have also been
identified as the dominant protein deposited in FTLD cases
previously classified as neuronal intermediate filament
inclusion disease (NIFID), basophilic inclusion body dis-
ease (BIBD) and atypical FTLD with ubiquitinated
inclusions [38, 43, 44, 53]. In contrast to ALS cases, FUS
mutations in FTLD are rare and the pathology is distinct.
The RNA binding proteins TATA-binding protein-associ-
ated factor (TAF15) and Ewings Sarcoma protein (EWS)
colocalise with FUS within inclusions in FTLD, which may
explain why these inclusions appear to be ubiquitinated.
Knockout of Fus in inbred strains of mice results in
chromosomal instability and perinatal death [20], but only
causes male sterility and enhanced sensitivity to radiation
in outbred animals [27]. Neither Fus-/- lines are reported
to show motor or cortical neuronal loss. Overexpression of
human ALS mutant FUS in adult transgenic rats, however,
results in progressive paralysis secondary to the degener-
ation of motor axons and substantial loss of cortical and
hippocampal neurons [21]. Overexpression of the wild-
type protein resulted in cognitive deficits in older animals
due to a loss of cortical and hippocampal neurons [21].
This indicated that mutant FUS is more toxic to lower
motor neurons than normal FUS, but that increased
expression of wild-type FUS is sufficient to cause
neurodegeneration.
Here we report the effect of wild-type FUS overex-
pression in inbred mice, and demonstrate significant loss of
motor neurons, coupled with a major motor and patho-
logical phenotype that recapitulates many aspects of FUS-
ALS. This phenotype appears to be crucially dependent on
the expression level of the protein, and is associated with a
significant shift in FUS localisation to the cytoplasm
without concomitant loss of FUS from the nucleus.
Materials and methods
Ethics statement
All experiments were performed under the terms of the
UK Animals (Scientific Procedures) Act 1986, and were
approved by the Kings College, London ethics review
panel.
Transgenic animals
For creation of transgenic mice, HA-tagged human FUS
cDNA was cloned into a modified mouse prion gene and
following removal of vector sequences, C57Bl/6/SJL
founder mice were produced by pronuclear injection as
described [30]. Animals were backcrossed onto C57Bl/6
three times prior to further breeding, following which
hemizygous animals were interbred to produce homozy-
gous offspring. Direct sequencing of the FUS transgene
was performed with Big-Dye Terminator v1.1 on an
ABI3130 genetic analyser (Applied Biosystems). All
sequence traces were analysed using Sequencher 4.10
(Gene Codes Corporation). Hemizygous animals were
identified using PCR with primers 50-GCAGGGCTATTC
CCAGCAGAGCAG and 30-CTGGTTCTGCTGTCCAT
AGCCCTG. Homozygous mice were identified using
qPCR with primers 50-CAGCAAAGCTATGGACAGC
and 30-GCGGTTATGGCAATCAAGAC and a FAM/
TAMRA tagged probe-AGCAGAACCAGTACAACAGC
AGCA. GAPDH was used as a housekeeping control. Each
sample was measured in triplicate. hFUS (?/-) mice will
be available through the Jackson Laboratory Repository.
They are assigned JAX stock no. 017916.
Evaluation of motor function and health
From 3 weeks of age, NTg (n = 9), hFUS (?/-) (n = 17)
and hFUS (?/?) (n = 11) mice were weighed on a weekly
basis, and general health status was recorded. Animals
showing signs of hind limb paralysis were monitored daily,
and disease end-stage and death was defined as the time
when animals could no longer obtain food or water, or had
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lost 25 % of their body weight, at which point they were
euthanized.
Motor strength and coordination were longitudinally
evaluated on the rotarod (Columbus Instruments), using a
5-min accelerating protocol starting at 2 rpm, and rising to
30 rpm throughout the 5-min testing period. Mice were
tested once a week, and latency to fall was recorded. All
mice received an initial training session of 2 min at 2 rpm
to acclimatise them to the equipment. Data were assessed
statistically by two-way analysis of variance (ANOVA)
followed by the post hoc Holm-Sidak test. At eight weeks
of age, the locomotor activity of animals was assessed in an
80-cm diameter circular open field environment. Mice were
allowed to explore the open field for 10 min. Trials were
monitored and analyzed using the Ethovision package
(Noldus, The Netherlands), and total distance travelled was
recorded. Data were assessed statistically by way of one-
way ANOVA followed by the post hoc Tukey test.
Histology and immunohistochemistry
Eleven-week-old, end-stage mice, and their age-matched
littermates were anaesthetised and transcardially perfused
with PBS, followed by 4 % paraformaldehyde (PFA) in
phosphate buffer. Brain and spinal cords were postfixed in
4 % PFA in 15 % sucrose for 5 h, cryoprotected in 30 %
sucrose for 24 h and cut into 30 lm sections on a cryostat.
For immunohistochemistry, the following antibodies
were used: rabbit anti-FUS (1:500, Sigma), rabbit anti-
ubiquitin (1:1000, DAKO), rat anti-HA (1:5000, Roche),
rabbit anti-GFAP (1:4000, DAKO), mouse anti-CD68
(1:2000, Serotec), goat anti-EWS (C-19; 1:50, Santa Cruz)
and TAF15 (TAF II p68; 1:50, Santa Cruz). Sections were
washed and incubated with the appropriate biotinylated
secondary antibody (1:1000, Vector), and then with an
ABC kit (Vector). Sections were imaged using a Zeiss light
or confocal microscope and axiovision software.
For motor neuron counts, perfused lumbar spinal cords
from four animals per genotype were serially sectioned,
and every 6th section (30 lm) was analysed. Sections were
mounted, dried, incubated overnight in 1:1 ethanol/chlo-
roform to de-fat the sections, stained for 10 min in warm
0.1 % cresyl violet, dehydrated and coverslipped. To
compare the number of motor neurons, large neurons
greater than 30 lm in diameter (based on their Fret’s
diameter as assessed by Image J software) in the anterior
horn of the lumbar spinal cord were counted in 15 sections.
Data were assessed statistically by one-way ANOVA,
followed by the post hoc Tukey test.
For muscle histology, gastrocnemius or tibialis anterior
muscles were dissected fresh, immediately frozen in iso-
pentane cooled in dry ice, and cryostat sections were cut
onto slides and stained with haematoxylin and eosin or
succinate dehydrogenase (SDH) activity to determine oxi-
dative capacity of the muscle fibres, as described [52].
Immunoblotting
For FUS and HA expression level analysis, whole brains of
four end-stage hFUS (?/?) and four age-matched hFUS
(?/-) and NTg animals were lysed in low salt buffer
(10 mM Tris, 5 mM EDTA, 10 % sucrose) with protease
inhibitors (Roche Diagonstics). For cytoplasmic and
nuclear fractionation, four brain samples for each genotype
were prepared as described earlier [19]. Briefly, snap-fro-
zen tissue was weighed and homogenised in buffer
containing 10 mM Hepes, 10 mM NaCl, 1 mM KH2PO4,
5 mM NaHCO3, 5 mM EDTA, 1 mM CaCl2, 0.5 mM
MgCl2 and protease inhibitors (109 vol/weight). After
10 min on ice, 2.5 M sucrose (0.59 vol/weight) was added.
Tissue was homogenized and centrifuged at 6,300g for
10 min. The supernatant was collected as the cytoplasmic
fraction. The pellet was washed 4 times in TSE buffer
[10 mM Tris, 300 mM sucrose, 1 mM EDTA, 0.1 %
IGEPAL (Sigma) and protease inhibitors 109 vol/weight],
homogenized and centrifuged at 4,0009g for 5 min.
Finally, the pellet was resuspended in RIPA buffer with
2 % SDS (5 9 vol/weight) as the nuclear fraction. Protein
samples were then separated by SDS/PAGE using 10 %
polyacrylamide gels, and transferred to nitrocellulose
membranes. Total FUS was recognised by a rabbit poly-
clonal antibody to FUS (1:2,000, Novus Biologicals), and
exogenous HA tagged human FUS was recognised by a
mouse monoclonal antibody to the HA tag (1:1,000, Cell
Signalling). Fluorescent secondary antibodies conjugated
to Dylight 680 or 800 nm (Thermo Scientific) were used to
detect protein levels, and results were visualised using the
Odyssey Imager (Licor). Data were normalised to GAPDH
(1:5,000, Sigma) or Lamin B1 (1:2,000, Abcam). Quanti-
tation of immunoblots was done using Image J software,
and data were analysed statistically by way of ANOVA
followed by the post hoc Tukey test.
In vivo physiological assessment of neuromuscular
function and motor unit survival
Functional analysis of hind limb muscle function was
undertaken at 70 days. NTg (n = 5), hFUS(?/-) (n = 6)
and hFUS(?/?) (n = 6) mice were anaesthetised (4.5 %
chloral hydrate, 1 ml/100 g of bodyweight, i.p) and pre-
pared for in vivo analysis of isometric muscle force as
previously described [24]. The distal tendons of the tibialis
anterior (TA) and extensor digitorum longus (EDL) hind
limb muscles were dissected free and attached by silk
thread to isometric force transducers (Dynamometer UFI
Devices, Welwyn Garden City, UK). The sciatic nerve was
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exposed and sectioned proximally. The length of the
muscles was adjusted for maximum twitch tension. The
muscles and nerves were kept moist with saline through
recordings and all experiments were carried out at room
temperature. Isometric contractions were elicited by stim-
ulating the nerve to the TA and EDL using square wave
pulses of 0.02 ms duration at supra-maximal intensity, via
silver wire electrodes. Contractions were elicited by either
a single stimulus for twitch tension or trains of stimuli at
frequencies of 40, 80 and 100 Hz for tetanic tension. The
maximum twitch and tetanic tension was measured using a
computer and Picoscope software (Pico Technology,
Cambridgeshire, UK).
Following recording of isometric tension, the contractile
and fatigue characteristics of EDL muscles were deter-
mined. The time to peak (TTP) was calculated by
measuring the time taken (ms) for the muscle to elicit peak
twitch tension and the half relaxation time (the time taken
for the muscle to reach half relaxation from peak con-
traction) was also calculated. In addition, the resistance of
the EDL muscles to fatigue was assessed by repeated
stimulation at 40 Hz for 250 ms every second for 3 min.
The tetanic contractions were recorded on a Lectromed
Multitrace 2 recorder (Lectromed Ltd, UK). The decrease
in tension after 3 min of stimulation was measured and a
fatigue index (FI) was calculated, where a FI approaching a
value of 1.0 indicating that a muscle is very fatigable [52].
The number of motor units innervating the EDL muscles
was determined by stimulating the nerve with stimuli of
increasing intensity, resulting in stepwise increments in
twitch tension due to successive recruitment of motor
axons with increasing stimulus thresholds. The number of
stepwise increments was counted to give an estimate of the
number of functional motor units in the EDL muscles [52].
Results
Overexpression of human wild-type FUS causes
progressive paralysis and death in mice
From 33 potential founders, only 3 were shown to carry the
human FUS (hFUS) construct, with an N-terminal HA-tag,
and under the control of the mouse prion protein (PrP)
promoter. The presence of the human wild-type FUS
transgene was confirmed using direct sequencing in all three
founders. Although all three founders bred, only one
founder generated F1 mice that were transgenic for FUS
and could be bred forward onto a C57B6 background.
Difficulties in producing constitutively expressing trans-
genic animals appear to be a feature of both Fus and TDP-
43 models, with other reports featuring a single line of mice
[56]. Western blots of brain lysates from the PrP-hFUS F3
generation mice showed that the exogenous hFUS protein
has a slightly higher molecular weight than endogenous
mouse FUS due to eight additional amino acids and the
presence of the HA-tag (Fig. 1a). The HA-hFUS expression
profile of major organs showed that the PrP-hFUS transgene
was expressed highest in the brain, spinal cord and testis,
with much lower expression in other tissues, which is typ-
ical for gene expression driven-PrP promoter [5] (Fig. 1d).
Quantification of expression indicated that total FUS
expression detected in the brain of hemizygous animals
[hFUS (?/-)] was only 1.4-fold higher than non-transgenic
(NTg) animals (Fig. 1a, b). In order to increase transgene
dose, we generated ‘‘homozygous’’ mice [hFUS (?/?)],
which have a 1.9-fold increase in HA-hFUS expression
compared to their hFUS (?/-) littermates (Fig. 1a). This
increase however was associated with a down-regulation of
endogenous murine Fus in transgenic animals (Fig. 1a, c),
with levels 0.86 [hFUS (?/-)] and 0.62 [hFUS (?/?)] fold
lower than NTg animals. Thus, hFUS (?/?) mice have only
a 1.7-fold increase in total FUS levels compared to their
NTg littermates (Fig. 1a, b). Immunohistochemistry using a
HA-tag antibody to selectively visualise the exogenous
hFUS protein showed expression throughout the spinal cord
(Fig. 1e–g), and in the cortex (Fig. 1h–j) in both (?/-) and
(?/?) hFUS mice.
Weight, general health and motor function, using the
accelerating rotarod paradigm, were assessed on a weekly
basis from three weeks of age. Animals were born at
Mendelian ratios, and were indistinguishable from their
NTg littermates until 4 weeks of age when the (?/?)
animals began to develop a tremor (Online resource Movie
S1) and show mild signs of hind limb dysfunction char-
acterised by a slightly stilted gait (Online resource Movie
S2). From 4 weeks, hFUS (?/?) mice displayed a failure
to gain weight normally (Fig. 2a, e) and a rapid decline in
their motor function, displaying a significant reduction in
performance on the accelerating rotarod compared with
NTg and hFUS (?/-) littermates (Fig. 2b). By 8 weeks of
age, hFUS (?/?) mice showed a significant reduction in
general locomotor activity in an open field environment
compared to their NTg and hFUS (?/-) littermates
(Fig. 2c). They displayed signs of progressive hind limb
paralysis with a severely stilted gait, an inability to raise
their pelvis off the ground (Online resource Movie S3) and
a failure to splay hind limbs normally when lifted by their
tail (Fig. 2f). Following the onset of hind limb paralysis at
7–8 weeks, hFUS (?/?) mice displayed signs of rapid
disease progression, and were euthanized by 10–13 weeks
because they were unable to obtain food or water, or had
lost 25 % of their total body weight. The average survival
time for hFUS (?/?) mice was 82 ± 12 days (Fig. 2d). In
contrast, hFUS (?/-) animals gained weight normally,
displayed no significant motor dysfunction or signs of ill
276 Acta Neuropathol (2013) 125:273–288
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health, and appear to have a life span comparable with their
NTg littermates (at least 104 weeks to date).
Motor dysfunction and death is accompanied
by an increase in cytoplasmic FUS but no ubiquitinated
FTLD-FUS-like inclusions
The pathological hallmarks of FTLD-FUS cases are ubiq-
uitin-positive cytoplasmic inclusions containing FUS in
neurons within the frontal and temporal lobes [43, 48]. In
contrast, ALS-FUS cases are characterised by ubiquitin-
negative FUS-positive inclusions within motor neurons in
the spinal cord and brain stem [55]. We therefore examined
the localisation of FUS and ubiquitin in the brains and
spinal cords of hFUS mice using immunohistochemistry.
Intense FUS staining, with numerous ring-like perinu-
clear inclusions (Fig. 4j), was observed in end-stage hFUS
(?/?) mice, and to a lesser extent in age-matched hFUS
(?/-) animals, in layer V neurons of the motor and
somatosensory cortices, the insular cortex, the neostriatum
and the Purkinje cells of the cerebellum (Figs. 3, 4).
Intense staining was also seen in a subset of pyramidal cells
in the CA3 region of the hippocampus (Fig. 3). In general,
FUS immunoreactivity in hFUS (?/-) mice was confined
predominantly to the nuclear and perinuclear area of neu-
rons (Fig. 4b, d), with a distribution similar to that seen in
NTg animals (Fig. 4a). In contrast, hFUS (?/?) mice also
displayed diffuse FUS staining throughout the cytoplasm of
cortical neurons (Fig. 4c, e, f) with no apparent loss of
nuclear FUS.
FUS, identified as a predominantly nuclear protein,
accumulates and aggregates in the cytoplasm in both FUS-
ALS and FUS-FTLD [43, 55] and the apparent increase in
cytoplasmic staining in hFUS (?/?) mice suggests that FUS
overexpression in these animals may significantly increase
cytoplasmic FUS levels. To further investigate this
Fig. 1 Overexpression of hFUS in mice dose dependently decreases
endogenous Fus expression. a Western blotting of brain lysate from
NTg and hFUS (?/-) and (?/?) mice using an anti-FUS antibody
showed a slight shift to a higher molecular weight due to the presence
of the HA tag and the larger protein size, and there was a dose-
dependent increase in HA-hFUS and total FUS expression in
transgenic animals (b), accompanied by a concomitant decrease in
endogenous Fus expression (c) (mean ± SEM; *p \ 0.05). d Western
blotting of tissue lysates with anti-HA antibody showed highest levels
in brain, spinal cord and testis, with lower levels in skeletal muscle
(Gastroc gastrocnemius), heart and other tissues. (e–j) Immunohisto-
chemistry with anti-HA antibody showed expression of the hFUS
protein throughout the spinal cord (e–g) and in the cortex (h–j; scale
bar 100 lm) in both hFUS (?/-) (f, i) and (?/?) (g, j) mice, which
was absent in NTg animals (e, h)
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possibility, FUS levels in nuclear and cytoplasmic fractions
prepared from brain samples were analysed by immuno-
blotting. In the brain, hFUS (?/-)and (?/?) animals show a
significant, and dose-dependent increase in nuclear FUS
levels compared to NTg controls (p = 0.044 and 0.006,
respectively; Fig. 4g, i), in contrast, cytoplasmic FUS levels
were unchanged in hFUS (?/-) animals (p = 0.593), but
rose dramatically in hFUS (?/?) mice (p = 0.002; Fig. 4g,
h). Thus, localisation of FUS to the cytosol appears to be
critically dependent on the level of FUS expression.
Ubiquitin staining in the brain revealed an increase in faint
diffuse, ring-like staining in the motor and somatosensory
cortices of hFUS (?/?) mice, together with some more
intensely stained ovoid structures in a subset of cells (Fig. 5c,
d) while some minor staining was also observed in hFUS
(?/-) (Fig. 5b) animals compared to their NTg littermates
(Fig. 5a). There was no significant ubiquitin staining present
in other brain regions. There was no obvious colocalisation
between hFUS and ubiquitin staining in the cortex in hFUS
(?/?) mice (Fig. 5e), rather, some neurons showed ring-like
FUS structures with the ubiquitin staining appearing to
encircle these concentrically, while other cells displayed
diffuse cytoplasmic FUS staining, with small ubiquitin foci,
and no apparent colocalisation between the two proteins. The
identity of the more intensely stained ubiquitin-positive
structures observed in some cells in the cortex is not currently
clear, however, they do not appear to display any obvious
colocalisation with Fus.
There was no sign of neuronal loss and markers for
astroglial (GFAP) and microglial (CD68) reactivity were
negative throughout the brain providing no evidence of an
inflammatory reaction to a more subtle neurodegenerative
processes in hFUS (?/-) or (?/?) mice up to 12 weeks
(Online resource Fig S1). Given the recent report that
FTLD-FUS is distinguished from ALS-FUS by the pres-
ence of Ewing’s Sarcoma protein (EWS) and TATA-
binding protein-associated factor 15 (TAF15) colocalising
with FUS pathology [41], we also looked for the presence
Fig. 2 Overexpression of hFUS
in mice results in motor
dysfunction and premature
death. a hFUS (?/?) (filled
triangles) mice show a failure to
gain weight from 4 weeks of
age, and are significantly lighter
than their NTg (filled circle) and
hFUS (?/-) (filled rectangle)
littermates from 5 weeks old
mice. In addition, they display a
significant reduction in weight
from their maximum at
11 weeks of age. b hFUS (?/?)
mice display significant
impairment and rapid decline in
performance on the rotarod
from 4 weeks of age. c 8-week-
old hFUS (?/?) mice display a
significant reduction in
locomotor activity compared to
their NTg and hFUS (?/-)
littermates. All data shown are
mean ± SEM; *p \ 0.05.
d Survival curve showing an
average survival of
82 ± 12 days for hFUS (?/?)
mice, while hFUS (?/-)
survival does not significantly
differ from NTg mice.
e Representative example of an
8-week-old hFUS (?/?) mice
(right animal) compared to its
NTg littermate (left animal).
f Abnormal hind limb splay in
8-week-old hFUS (?/?) mice
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of these proteins in our mice, but found no evidence of
pathology or colocalisation of FUS with either protein
(Online resource Fig S2).
Overexpression of human wild-type FUS results ALS-
like pathology in the spinal cord
In the spinal cord of hFUS (?/?) mice, FUS staining
showed globular and granular cytoplasmic inclusions
similar to those seen in human FUS-ALS patients [28, 55]
(Fig. 6c, d), which were absent in hFUS (?/-) and NTg
animals (Fig. 6a, b). Ubiquitin immunohistochemistry
revealed occasional neurons in hFUS (?/?) mice with
granular ubiquitinated deposits (Fig. 6g, h) but there was
no colocalisation with FUS inclusions (Fig. 6i), which is
similar to the pathology observed in FUS-ALS cases [55].
Neuronal cell counting demonstrated a significant
(*60 %) loss of a-motor neurons in the anterior horn of
the lumbar spinal cord in hFUS (?/?) animals compared
to their hFUS (?/-) (p = 0.034) and NTg (p = 0.012)
Fig. 3 FUS staining in brain regions associated with motor or
cognitive function in hFUS animals. Overexpression of HA-hFUS
resulted in a dose-dependent increase in FUS staining in the
somatosensory (a–c) and insular (e–g) cortices, the neostriatum
(i–k), the Purkinje cells of the cerebellum (m–o) and a portion of the
CA3 region of the hippocampus (q-s) (scale bar 50 lm). Higher
power images of homozygous animals reveal skein-like and diffuse
cytoplasmic staining in the somatosensory (d) and insular (h) cortices,
the neostriatum (i) and the Purkinje cells of the cerebellum (p) and to
a much lesser extent in the hippocampus (t) (scale bar 20 lm)
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littermates (Fig. 7). This was associated with an increase in
astrogliosis in the anterior horn (Fig. 8c), and to a lesser
extent microgliosis in both the anterior horn (Fig. 8f) and
the white matter tracts, in particular the dorsal columns
(Fig. 8i). Haematoxylin and eosin staining of end-stage
spinal cord tissues reveals no evidence of eosiniphilic
aggregates in the cell bodies of surviving motor neurons in
hFUS (?/?) mice compared to their NTg and hFUS (?/-)
littermates (Fig. 8j, l), differing from reports in mice
overexpressing wild-type TDP-34 [49], where these
aggregates are proposed to be abnormal accumulations of
mitochondia. Our finding suggests that Fus and TDP-43
Fig. 4 hFUS overexpression results in a significant shift in cytoplas-
mic localisation in homozygous animals. (a–c) FUS expression in the
motor cortex was increased in both (?/-) (b) and (?/?) (c) hFUS
mice compared to their NTg (a) littermates (scale bar 50 lm). d A
higher power image of the hFUS (?/-) section reveals mainly
nuclear and perinuclear FUS staining (scale bar 20 lm). e A higher
power image of the hFUS (?/?) section shows many neurons with
cytoplasmic staining (black arrows) that is absent in both hFUS (?/-)
and NTg mice. In addition, ring-like perinuclear FUS staining is
evident in numerous cells in both hFUS (?/?) (red arrows), and to a
lesser extent hFUS (?/-) animals (scale bar 20 lm). f A second high
power image showing cytoplasmic staining in cortical neurons of the
hHUS (?/?) brain even in the absence of abnormal ring-like
accumulations. g Western blotting of nuclear and cytosolic fractions
from brain demonstrated an increase in both cytosolic and nuclear
FUS levels. GAPDH was used as the marker for the cytosolic fraction,
and Lamin B1 for the nuclear fraction. h Quantification of cytosolic
FUS levels, showing an increase in FUS levels only in hFUS (?/?)
animals (*p \ 0.05). i Quantification of nuclear FUS levels, showing
an expression-dependent increase in FUS in transgenic mice
(*p \ 0.05). j A representative confocal image demonstrating the
ring-like nature of the inclusions observed in hFUS (?/?) cortical
neurons (scale bar 20 lm)
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may have differential effects on mitochondrial distribution,
and hence their involvement in ALS may be via distinct
mechanisms, although given the significant loss of motor
neurons in our hFUS (?/?) mice we cannot rule out
mitochondrial mislocalisation in the lost cells as a disease
factor.
Muscle histology from end-stage hFUS (?/?) mice
showed marked grouped atrophy of muscle fibres charac-
teristic of denervation seen in muscle from ALS patients
(Fig. 8o). Interestingly, age-matched hFUS (?/-) animals
showed a milder disorganisation of their muscle fibres
(Fig. 8n) compared to their NTg littermates (Fig. 8m).
There was also a modest increase in the number of reactive
astroglia (Fig. 8b) and the occasional activated microglial
cell seen in the white matter tracts and anterior horn of
hFUS (?/-) animals (Fig. 8e, h). Although neuronal
counts were lower in hFUS (?/-) mice than in Ntg lit-
termates these did not reach statistical significance
(p = 0.53).
Overexpression of wild-type FUS results in impaired
neuromuscular function
Neuromuscular function was assessed in anaesthetised
mice at 70 days of age. Maximum single twitch and tetanic
force were determined in tibialis anterior (TA) and exten-
sor digitorum longus (EDL) hind limb muscles.
Twitch and tetanic force recordings showed that the TA
muscles in hFUS (?/?) mice were approximately 80 %
weaker than in NTg (both p \ 0.001) animals. In contrast,
hFUS (?/-) TA twitch and tetanic force recordings were
not significantly different from NTg animals indicating that
there was no motor neuron dysfunction in these mice. A
similar loss of muscle force was observed in hFUS (?/?)
mice EDL compared to NTg mice, with a 20 % reduction
in both twitch (p \ 0.001) and tetanic force (p = 0.024;
Online resource Fig. S3 and 9a, b).
Changes in the contractile characteristics of TA and
EDL muscles of hFUS (?/?) mice were also observed.
Muscle relaxation was significantly longer in both the TA
and EDL of hFUS (?/?) mice compared to hFUS (?/-)
and NTg mice (p = 0.005 and 0.006, respectively; Fig. 9c,
d). In addition, alterations in the fatigue characteristics of
TA and EDL muscles of hFUS (?/?) mice were observed.
Fast-twitch muscles are usually very fatiguable and cannot
maintain force when repetitively stimulated. A Fatigue
Index (FI) was calculated for TA and EDL by expressing
the force generated after a 3-min period of stimulation as a
ratio of initial force produced, where a FI of 1.0 indicates
that the muscle is resistant to fatigue. In the EDL of hFUS
(?/?) mice, there was a clear increase in fatigue resis-
tance, compared to hFUS (?/-) and NTg mice (p = 0.08).
These findings indicate that there is a loss of fast-twitch
muscle fibres in EDL of hFUS (?/?) mice (Fig. 9g, h).
Cross sections of TA muscles were stained with succinate
dehydrogenase (SDH), confirming a loss of glycolytic fast-
twitch muscle fibres (Fig. 9g). Moreover, physiological
assessment of functional motor unit survival revealed that
20 % fewer motor units survived in EDL muscle of hFUS
(?/?) mice (Fig. 9e).
Fig. 5 FUS staining does not colocalise with ubiquitin in the cortex.
a–c Ubiquitin positive neurons were increased in the motor cortex of
hFUS (?/?) (c) and to a much lesser extent (?/-) (b) animals
compared to NTg controls (a) (scale bar 50 lm), and d weak
ubiquitin staining is prevalent in hFUS (?/?) mice (scale bar
20 lm). e Fluorescent labelling of HA-tagged FUS and ubiquitin in
the motor cortex of a hFUS (?/?) mouse shows cytoplasmic FUS
deposits surrounded by ubiquitin, and diffuse granular cytoplasmic
Fus staining accompanied by small ubiquitin positive cytoplasmic
granules but no co-labelling of the two proteins (scale bar 5 lm)
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Discussion
ALS and FTLD are two neurodegenerative disorders that
fall within an overlapping clinical and pathological disease
spectrum that includes the TDP-43 and FUS proteinopa-
thies [31, 32, 40]. FUS and TDP-43 are structurally related
RNA-binding proteins that may have overlapping functions
and form complexes with other RNA-binding proteins [25].
Both proteins reside predominantly in the nucleus, and
shuttle between the nucleus and the cytoplasm to perform
various functions [3, 14, 18, 36]. It has been proposed that
both FUS and TDP-43 may induce disease via either a gain
of function within the cytoplasm, or a loss of function from
the nucleus. The loss of function hypothesis is supported by
evidence of nuclear depletion of TDP-43 in neurons con-
taining cytoplasmic inclusions [2, 12, 45], a finding that has
not yet been conclusively reported for FUS.
FUS accumulates within cytoplasmic inclusions in ALS
patients (and rarely FTLD cases) when it is associated with
FUS gene mutations [28, 54, 55]. FUS containing inclu-
sions have also been identified as the dominant pathology
in a subset of FTLD patients accounting for most cases that
have TDP-43 and tau negative pathology [38, 43, 48, 53].
We generated hemizygous and subsequently homozygous
FUS transgenic mouse lines expressing HA-tagged human
wild-type FUS at 1.4- and 1.9-fold above endogenous
levels in non-transgenic littermates (respectively).
Overexpression of human FUS resulted in significantly
decreased expression of mouse Fus. The overall pattern of
Fus positive staining in all animals, regardless of genotype,
was consistent with that previously reported [1], with
intense neuropil staining in the cord and to a lesser extent
the brainstem, together with nuclear staining throughout
the CNS, although neuropil staining throughout the brain
appears slightly increased in hFUS (?/?) mice compared
to their NTg and (?/-) littermates, which is consistent
with the increase in cytoplasmic Fus observed in these
mice.
Fig. 6 FUS and ubiquitin spinal cord pathology in hFUS mice.
a–c FUS expression in the anterior horn of the spinal cord was
increased in both (?/-) (b) and (?/?) (c) hFUS mice compared to
their NTg littermates (a) (scale bar 50 lm). d A higher power image
showing the presence of a FUS inclusion (arrow) in a large neuron of
a hFUS (?/?) animal. (scale bar 20 lm). There was no evidence of
inclusions in either hFUS (?/-) or NTg animals. e–g Abnormal
granular ubiquitin was only present in a few large neurons of hFUS
(?/?) (g) animals, with no significant staining in the anterior horn of
the spinal cord of either NTg (e) or hFUS (?/-) (f) animals (scale bar
50 lm). h A higher power image showing rather diffuse, granular
ubiquitin staining throughout two large neurons, with no obvious
large inclusions visible (scale bar 20 lm). i Fluorescent labelling of
HA-tagged FUS and ubiquitin in a neuron of the anterior horn of the
spinal cord of a hFUS (?/?) mouse shows multiple small FUS
inclusions in the cytoplasm of the cell with diffuse, low-level
ubiquitin staining throughout the cytoplasm, but no evidence of
HA-FUS and ubiqitin colocalisation (scale bar 5 lm)
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Although additional attempts were made, we were
unable to generate further viable transgenic lines over-
expressing human wild-type FUS under the control of the
Prion promoter for comparison to the line reported here.
This is similar to problems described in TDP-43 rodent
models of ALS [56, 59], and is likely to be due to selective
pressure against the expression of FUS above endogenous
levels during early development, given its apparent dose-
dependent toxicity in cellular models [7, 16, 23].
Homozygous transgenic mice developed a rapidly pro-
gressive motor deficit as measured by rotarod, locomotor
activity and neurophysiological testing. Tremor began
around 4 weeks and progressed to paralysis at
10–12 weeks, necessitating euthanasia. End-stage pathol-
ogy revealed approximately 60 % motor neuron loss from
the lumbar spinal cord. Many surviving neurons contained
FUS-positive, ubiquitin-negative inclusions in the spinal
cord, and there was evidence of microglial and astrocytic
activation in the anterior horn and white matter of the
dorsal columns. These changes are the pathological hall-
mark of human mutant FUS-mediated ALS cases [55].
Most ALS-related FUS mutations reside in the C-terminal
nuclear localising signal (NLS). They disrupt binding to the
nuclear transport factor, transportin, which impairs their
nuclear import, leading to cytoplasmic accumulation
within motor neurons and toxicty [13]. The degree of
cytoplasmic mislocalisation in cellular studies for each
ALS mutant appears to correlate with the age of disease
onset in ALS patients implying that cytoplasmic
mislocalisation is directly toxic [13]. Conversely, deletion
of the nuclear export signal strongly suppressed mutant
FUS toxicity in Drosophila, implying that cytoplasmic
localisation is required for neurodegeneration [29]. This
finding is supported by a recent study in C. elegans dem-
onstrating that cytoplasmic mislocalisation of FUS induced
by mutant FUS is sufficient to cause motor dysfunction,
even in the presence of functional levels of wild-type FUS
in the nucleus [39]. Here, we show that overexpression of
wild-type FUS is toxic to motor neurons when it accu-
mulates in the cytoplasm. Thus, the toxicity of FUS
mutations may be solely due to their impact on nuclear
import [6, 13, 17, 22, 26]. Although nuclear Fus levels also
increase in these animals, it is unlikely that this is
responsible for the main pathological phenotype, as
hemizygous animals show a significant increase in nuclear
Fus, and yet show no signs of overt phenotype after two
years of age. In the brain, there was no evidence of mi-
croglial and astrocytic activation or neuronal loss despite
abundant granular and skein-like FUS-positive inclusions
in the cytoplasm of multiple neuronal populations. Given
the early onset severe motor dysfunction in these animals,
it was not possible to assess them for cognitive impairment.
In contrast, hemizygous animals have no gross pathological
changes in either the brain or spinal cord at 12 weeks and
show no evidence of motor dysfunction out to 104 weeks.
They did however, show mild astroglial and microglial
activation in the spinal cord at 12 weeks. There were also
subtle changes within muscle architecture in hemizygous
mice, without signs of neuronal loss or neurophysiological
evidence of neuromuscular dysfunction. A cohort of
hemizygous mice is currently being aged and will be
screened for signs of cognitive dysfunction. Recent find-
ings in FUS transgenic rats overexpressing wild-type FUS
revealed cognitive defects in aged animals [21]. Fus
overexpression within the CNS of our mice is variable,
with some cell populations displaying more expression
than others. This suggests that the PrP-driven expression
may display some mosaic expression properties in this
model. However, the lack of obvious cell loss in several
brain cell populations showing high levels of Fus overex-
pression supports the idea that lower motor neurons are
selectively vulnerable to Fus overexpression. We therefore
conclude that the overexpression of human wild-type FUS
is particularly toxic to motor neurons.
These findings are consistent with recent reports of wild-
type FUS toxicity in other species. Overexpression of wild-
type Fus results in punctate cytoplasmic aggregates and
dose-dependent toxicity in yeast [16, 23] and apoptotic cell
death in human prostate cancer cells [7]. Overexpression of
human wild-type FUS restricted to neurons in Drosophila
results in a dose-dependent decrease in life span [37], and
an impaired locomotor phenotype accompanied by
Fig. 7 hFUS overexpression results in a loss of motor neurons in
homozygous animals. a–c Cresyl violet staining of motor neurons in
the lumbar ventral horn of NTg (a), hFUS (?/-) (b) and hFUS (?/?)
(c) mice, showing a dearth of neurons present only in the hFUS (?/?)
animals (scale bar 100 lm). d Cell counting of motor neurons in the
lumbar anterior horn showed a significant loss of approximately 60 %
of motor neurons in hFUS (?/?) mice compared with non-transgenic
controls. In contrast hFUS (?/-) mouse motor neuron numbers were
not significantly different (*p \ 0.05)
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morphological abnormalities in motor neurons and neuro-
muscular junctions [8].
Overexpression of the R521C ALS FUS mutant in the
rat [21] resulted in an aggressive motor phenotype leading
to death of all animals by 10 weeks. This was accompanied
by disruption of the neuromuscular junction and a *10 %
motor neuron loss. They report some FUS mislocalisation
to the cytoplasm without discrete inclusion formation and
although ubiquitinated inclusions were observed within
spinal neurons they do not colocalise with FUS. Rats
transgenically overexpressing wild-type human FUS have
no motor phenotype or spinal cord pathology but develop
cognitive dysfunction and neuron loss in the frontal cortex
and dentate gyrus by 12 months. Here again, FUS localised
Fig. 8 Increased neuroinflammation in the cord of hFUS mice
accompanied by muscle atrophy. a–c Significant FUS expression-
dependent increases in astrogliosis, detected using GFAP immuno-
histochemistry, were apparent in the anterior horn of the spinal cord
in both (?/-) and (?/?) hFUS mice (scale bar 20 lm). d–i FUS
expression-dependent increases in microglial activation, detected
using CD68 immunohistochemistry, were apparent to a mild extent in
the anterior horn of the spinal cord, (d–f) and more dramatically in the
dorsal columns (g, h) of hFUS (?/?) mice. A very few cells were
also present in hFUS (?/-) animals (arrows) (scale bar 20 lm).
j–l Haematoxylin and eosin staining of spinal cord shows no evidence
of eosinophilic inclusions in surviving motor neurons of end-stage
hFUS (?/?) mice. m–o Haematoxylin and eosin staining of muscle
showing scattered and grouped muscle fibre atrophy, characteristic of
motor neuron degeneration in hFUS (?/?) mice, with some evidence
of muscle fibre disorganisation in hFUS (?/-) animals (scale bar
20 lm)
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to the nucleus with little cytoplasmic mislocalisation and no
inclusions. Ubiquitinated inclusions were detected in FUS
expressing cells but did not colocalise with FUS. Our
transgenic mice display a progressive and lethal motor
phenotype similar to that seen in the rats expressing mutant
FUS. In our mice, neuronal loss was only seen in homozy-
gous animals where significant cytoplasmic mislocalisation
of FUS was observed without loss of nuclear FUS. Both
mouse and rat transgenic models support a toxic gain of
function due to the accumulation of FUS rather than a loss of
nuclear function.
Our mice constitutively overexpress wild-type human
FUS under the control of the prion promoter. In compari-
son, the transgenic rat lines, wild-type and mutant,
employed a cDNA construct driven by the Tet-off TRE and
tTA promoter system whereby expression is induced only
on weaning [21]. Thus, it is possible that the different
promoter systems and onset of expression, combined with
species and strain variations, may account for some of the
different specific effects that overexpression of the wild-
type FUS has in these two models. Nevertheless, neuro-
degeneration was observed in both our wild-type FUS
mice, and the wild-type FUS transgenic rats, demonstrating
that FUS overexpression is pathogenic.
The phenotype observed in our hFus (?/?) mice bears
some similarities to mice overepxressing wild-type TDP-43
[57], such as a failure to gain weight, tremor, and motor
dysfunction. Since both Fus and TDP-43 are RNA-binding
Fig. 9 Neuromuscular function in hFUS mice. a, b Tetanic force
production of the hind limb TA (a) and EDL (b) muscles was
significantly reduced in hFUS (?/?) mice compared to NTg mice,
with a deficit in force of approximately 80 and 20 % in the TA and
EDL, respectively. c, d Muscle relaxation in both muscles was
significantly slowed in hFUS (?/?) mice compared to both NTg and
hFUS (?/-) animals. e, f Motor unit number was recorded from the
EDL of all groups. Typical examples of motor unit traces from an
NTg and hFUS (?/?) mice are shown in (e), and the results of mean
motor unit survival are summarised in the bar chart (f) demonstrating
a loss of 20 % of motor units in hFUS (?/?) mice. g Characteristic
fatigue traces from a NTg and hFUS (?/?) mouse, generated by
tetanic stimulation of the fast EDL muscle over 180 s. Each tetanic
contraction is represented by a single line in the trace, and the length
of the line is relative to the force produced. The length of the force
trace at Ft180 (time = 180 s) as a ratio of that at Ft0 gives a fatigue
index (FI). Wild-type mice lose a large proportion of force at the end
of the stimulation period compared with the beginning of the trace,
thus having a low FI. In contrast, in hFUS (?/?) mice the EDL is less
fatigable, as indicated by the higher FI. On the right of each trace is a
cross-section of TA muscle obtained from NTg and and hFUS (?/?)
mice stained for SDH. NTg animals display a mix of darkly stained,
oxidative type I fibres and lightly stained, less oxidative fast type II
fibres. In contrast, hFUS (?/?) mice display mainly dark staining,
suggesting a transformation of muscle fibres into a slower phenotype.
h Summary of FI in EDL muscle of NTg and hFUS (?/-) and (?/?)
mice.
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proteins, the similarities in dysfunction that occur in
response to overexpression of either protein may suggest
that dysfunctions in RNA processing are important in the
development of disease.
We conclude that overexpression of wild-type human
FUS will induce motor neuron degeneration in mice when
protein levels are sufficient to cause significant cytoplasmic
accumulation. Our mice reproduce many aspects of the
clinical phenotype and pathological features of human
mutant FUS-mediated ALS, and as such, this model will
facilitate the exploration of disease mechanisms and
opportunities for therapy.
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